Receptor News and Research

RSS

Human immune system can help predict recurrence, overall breast cancer survival

A study published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, held April 2-6, showed how evaluating the immune response in the tumor microenvironment may help researchers better target therapy in breast cancer.

4 Apr 2011

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

Bristol-Myers Squibb Company today announced results from the Phase IIb EMERGE clinical trial, in which treatment with the investigational compound PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response in genotypes 1, 2, 3, and 4, and complete early virologic response in genotypes 1 and 4 than the standard regimen of PEG-Interferon alfa and ribavirin in treatment-naïve patients chronically infected with hepatitis C.

4 Apr 2011

New research reveals potential treatment for HO in children, soldiers

Promising new research reveals a potentially highly effective treatment for heterotopic ossification, a painful and often debilitating abnormal buildup of bone tissue. HO comes in two main forms—one that appears in children and is congenital, another that strikes wounded military personnel and surgery patients and is triggered by severe injuries and wounds.

4 Apr 2011

New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability

Highly exciting new data presented today at the International Liver Congress found Pegylated Interferon-lambda shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha, the current standard of care in chronic HCV.

4 Apr 2011

Scientists sequence tumor genomes from 50 breast cancer patients

In one of the largest cancer genomics investigations reported to date, scientists have sequenced the whole genomes of tumors from 50 breast cancer patients and compared them to the matched DNA of the same patients' healthy cells.

4 Apr 2011

Breast cancer genome reveals potential therapeutic targets

Scientists have sequenced the entire genomes of tumors from 50 breast cancer patients and found more than 1,700 gene mutations, most of which were unique to individual patients. The researchers at Washington University in St. Louis and the Siteman Cancer Center suggest that this variability and uniqueness made it difficult to predict outcomes of the cases.

3 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

Array BioPharma to unveil new findings about its anti-cancer programs at AACR Annual Meeting

Array BioPharma Inc. today announced that five abstracts have been selected for presentation at the American Association for Cancer Research Annual Meeting, being held from April 2-6, 2010, at the Orange County Convention Center in Orlando, Fla.

2 Apr 2011

University of Houston part of multi-investigator $5.2M CPRIT award for prostate cancer research

A pair of University of Houston (UH) researchers and their colleagues will begin work to develop new methods for treating the most severe form of prostate cancer thanks to $5.2 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).

2 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

Biocept, academic collaborators' posters on CTCs to be presented at AACR meeting

Biocept, Inc. today reported that its scientists and academic collaborators will present four posters at the 102nd Annual Meeting of the American Association for Cancer Research taking place in Orlando, Florida April 2-6, 2011.

1 Apr 2011

Study shows immune therapy can prevent pregnancy in mammals including humans

Researchers at Weill Cornell Medical College have shown that it is possible to immunize mammals to control fertility. They say their technique could possibly be used on other mammals -- including humans -- because fertility hormones and their receptors are species-non-specific and are similar in both females and males.

1 Apr 2011

Obeticholic Acid safe and effective against Primary Biliary Cirrhosis

Results from an international study presented today at the International Liver Congress have shown Obeticholic Acid (OCA) is a safe and effective treatment in patients suffering from Primary Biliary Cirrhosis (PBC) as demonstrated by substantial decreases in the levels of alkaline phosphatase (AP) enzyme in the blood, a key marker for PBC.

1 Apr 2011

New study examines psychological, social challenges of women with breast cancer

When an aggressive form of breast cancer strikes a young woman, what kind of stress, anxiety and other psychological and social challenges does she face?

1 Apr 2011

New signaling pathway discovery sheds light on chronic dermatitis

A new signaling pathway, which is important for the regulation of the immune response and inflammation, was discovered by an international team of scientists led by prof Ivan Dikic from the Goethe University, Frankfurt, Germany.

1 Apr 2011

Anavex screening volunteers for phase I, first-in-human clinical study in Alzheimer’s

Anavex Life Sciences Corp. today announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is the first of a new class of wholly-owned, oral, disease-modifying compounds, which act through sigma-1 receptor agonist as well as muscarinic cholinergic effects and up-regulation of Bcl-2.

31 Mar 2011

Immune therapy can control fertility in mammals

31 Mar 2011

Protox reports net loss of $4.5 million for year ended December 31, 2010

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today announced financial results and achievements for the year ended December 31, 2010.

31 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis, which will evaluate Intercept's first-in-class farnesoid X receptor agonist obeticholic acid as a novel therapy for NASH.

30 Mar 2011

Receptor News and Research

Human immune system can help predict recurrence, overall breast cancer survival

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

New research reveals potential treatment for HO in children, soldiers

New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability

Scientists sequence tumor genomes from 50 breast cancer patients

Breast cancer genome reveals potential therapeutic targets

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Array BioPharma to unveil new findings about its anti-cancer programs at AACR Annual Meeting

University of Houston part of multi-investigator $5.2M CPRIT award for prostate cancer research

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

Biocept, academic collaborators' posters on CTCs to be presented at AACR meeting

Study shows immune therapy can prevent pregnancy in mammals including humans

Obeticholic Acid safe and effective against Primary Biliary Cirrhosis

New study examines psychological, social challenges of women with breast cancer

New signaling pathway discovery sheds light on chronic dermatitis

Anavex screening volunteers for phase I, first-in-human clinical study in Alzheimer’s

Immune therapy can control fertility in mammals

Protox reports net loss of $4.5 million for year ended December 31, 2010

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Intercept initiates OCA FLINT trial in patients with nonalcoholic steatohepatitis

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News